Clinical Trial of the WC360 SiteSeal Adjunctive Compression Device Following Interventional Endovascular Procedures

NCT ID: NCT03234894

Last Updated: 2020-01-30

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-01
• Study Completion Date: 2020-09-01

Brief Summary

This Clinical Study is a pivotal study to evaluate the safety of the SiteSeal™ Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.

Detailed Description

The study design is a single arm with 90 patients. The primary endpoints measure the risk for common femoral nerve damage and common femoral artery laceration from the blind placement of a Z-stitch in the soft tissue above the femoral bundle.

The sample size is 90 patients. The project objective is to demonstrate the safety of the device.

Conditions

Bleeding

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SiteSeal Endovascular

After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.

There is a secondary metric as to patient reported pain on a 1-10scale.

Group Type: OTHER

SiteSeal Endovascular

Intervention Type: DEVICE

to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.

Interventions

SiteSeal Endovascular

to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.

Intervention Type: DEVICE

Other Intervention Names

SiteSeal Cardiovascular

Eligibility Criteria

Inclusion Criteria

1. Patients between the ages 19 to 90

2. Patient or his/her legally authorized representative, has given written informed consent for participation prior to the procedure

3. Procedure is an interventional procedure

4. Patient is willing to undergo all study procedures and adhere to data collection and follow-up requirements

5. Patient is a candidate for elective, non-emergent cardiac or peripheral vascular catheterization from the femoral artery approach

6. Patient is willing to have a pre/post procedure ultrasound.

Exclusion Criteria

1. Patients are <19 years old

2. Patients are >90years old

3. Patient has received GP IIb/IIIa inhibitors

4. Patient or patient's representative is unable to provide written informed consent.

5. Patient is unable or unwilling to adhere to data collection and follow-up requirements

6. Procedure is emergency PCI

7. Patient is on dialysis

8. Patient has a known diagnosis of fibromyalgia

9. Patients with acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤ 48 hours before this catheterization procedure.

10. Patients with systolic blood pressure < 90 mm Hg at the end of the catheterization procedure

11. Patients who are immunocompromised

12. Patients with preexisting systemic infection or local infections at the access site

13. Patients who are known or suspected to be pregnant, or are lactating

14. Patients who have undergone prior or recent use of an intra-aortic balloon pump through the arterial access site above the inguinal ligament

15. Patients who have undergone prior vascular closure device use in the ipsilateral common femoral artery ≤ 30days before this catheterization procedure

16. Patients who have undergone prior use of manual or mechanical compression for closure in the ipsilateral common femoral artery ≤30 days before the catheterization procedure

17. Patients requiring a repuncture at a site previously punctured within 48 hours of the catheterization procedure

18. Patients who have undergone an antegrade puncture

19. Patients with puncture sites believed to be in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries

20. Patients with puncture tract angle >55°

21. Patients who are suspected to have experienced a femoral artery back wall puncture or who underwent > 1femoral artery puncture during the catheterization procedure

22. Patient with significant anemia (hemoglobin < 10 g/dL, Hct < 30%)

23. Patients with a known bleeding disorder, including thrombocytopenia (platelet count < 100,000 cells/μL), thrombasthenia, hemophilia, or von Willebrand's disease

24. Patients with systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at the end of this catheterization procedure, unless systolic and/or diastolic pressure was lowered by pharmacological agents prior to the end of the catheterization procedure

25. Patients with a baseline INR >1.5 (e.g., on warfarin therapy)

26. Patients whose ACT >300seconds at the end of the catheterization procedure

27. Patients who have undergone administration of low molecular weight heparin (LMWH) within 8hours of this catheterization procedure

28. Patients in whom continued heparin or other anticoagulant/antiplatelet therapy is planned for this patient (with the exception of glycoprotein IIb/IIIa inhibitor therapy) during the first few hours following the catheterization procedure

29. Patients having a complication or complications at the femoral artery access site during the catheterization procedure including bleeding, hematoma, intraluminal thrombus, pseudoaneurysm, or arteriovenous fistula

30. Patients with an ipsilateral or bilateral lower extremity amputation(s)

31. Patient known to require extended hospitalization (e.g., patient is undergoing cardiac surgery)

32. Patients who have a planned endovascular procedure within the next 30days after the catheterization procedure

33. Patients who are currently participating in another investigational study that has not concluded the follow-up period

34. Patients who have already participated in the IDE study

35. Patients who cannot adhere to or complete the study for any reason including but not limited to geographical residence or life-threatening disease

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wound Care 360, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elias Kassab, MD

Role: PRINCIPAL_INVESTIGATOR

MOVI

Matthew Earnest, MD

Role: PRINCIPAL_INVESTIGATOR

University of Kansas Medical Center

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

G150106/A001

Identifier Type: -

Identifier Source: org_study_id